![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1452570
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°Europe Fluorescence In-Situ Hybridization Imaging Systems Market Forecast to 2030 - Regional Analysis - By Product, Application, and End User |
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº 2022³â 2¾ï 6,800¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 4¾ï 6,070¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 7.0%·Î ÃßÁ¤µË´Ï´Ù.
Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ÀÇ ±â¼ú ¹ßÀüÀ¸·Î À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀ» ÃËÁø
Çü±¤ in-situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛÀº ±â¼ú ¹ßÀüÀÇ ±Þ°ÝÇÑ Áõ°¡·Î ÀÎÇØ ´«ºÎ½Å ÁøÈ¸¦ °ÅµìÇϰí ÀÖÀ¸¸ç, ±× °á°ú ÃÖ÷´Ü Çõ½ÅÀÌ À¯ÀüÀÚ ¿¬±¸ ¹× Áø´ÜÀÇ ÆÇµµ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü¿¡´Â Çâ»óµÈ ±¤ÇÐ, º¸´Ù ¹Î°¨ÇÏ°í ´Ù¾çÇÑ Çü±¤ ¿°·á, Á¤±³ÇÑ ÀÚµ¿È ±â´É µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¾÷±×·¹À̵åµÈ ±â´É°ú ÅëÇÕµÈ ÃֽŠÇü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛÀº ´õ ³ôÀº °¨µµ, °³¼±µÈ À̹ÌÁö ÇØ»óµµ, ´õ ºü¸¥ ó¸® ½Ã°£À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸¸¦ ÅëÇØ Çü±¤ in-situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ÀÇ Àû¿ë ¹üÀ§´Â ¾Ï Áø´Ü¿¡¼ À¯ÀüÀû ¼ÒÀÎ °Ë»ç±îÁö È®´ëµÇ°í ÀÖÀ¸¸ç, 2021³â 7¿ù BioView¿Í Capio Biosciences´Â ÀüÇ÷¿¡¼ ¼øÈ¯ Á¾¾ç¼¼Æ÷(CTC)¸¦ äÃëÇÏ´Â Ç÷§ÆûÀ» °øµ¿ °³¹ßÇß½À´Ï´Ù. ÀüÇ÷¿¡¼ ¼øÈ¯Á¾¾ç¼¼Æ÷(CTC)¸¦ äÃëÇÏ´Â Ç÷§ÆûÀ» °øµ¿ °³¹ßÇß½À´Ï´Ù. ¾ç»çÀÇ ±â¼úÀ» ÅëÇÕÇÏ¿© CTC ¾×ü»ý°ËÀÇ ´Ù¿î½ºÆ®¸² ºÐ¼®À» °³¼±Çϱâ À§ÇØ ³ë·ÂÇß½À´Ï´Ù. ¸¶Âù°¡Áö·Î BioView¿Í Capio Biosciences´Â 2020³â 12¿ù RUBYnanomed¿Í Çù·ÂÇÏ¿© ¾Ï °ËÃâÀ» °ÈÇϱâ À§ÇØ ÀÓ»ó¿¡¼ CTC ±â¼úÀÇ ¼ö¿ë°ú äÅÃÀ» °¡¼ÓÈÇÒ ¼ö ÀÖ´Â µ¶ÀÚÀûÀÎ À̹Ì¡ ¼Ö·ç¼ÇÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ Çü±¤ in-situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüÀº Çü±¤ in-situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀÇ ±â¾÷¿¡°Ô Å« ºñÁî´Ï½º ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå °³¿ä
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº ¼¼°è ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº °·ÂÇÑ ÀÇ·á±â±â Á¦Á¶ ´É·Â°ú À¯·´ °¢±¹ÀÇ ³ôÀº ¾Ï À¯º´·ü·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¶ÀÏÀº ¼¼°è¿¡¼ °¡Àå À¯¸®ÇÑ ÀÇ·á±â±â ½ÃÀå Áß ÇϳªÀÔ´Ï´Ù. ±¹Á¦¹«¿ª±¹(ITA)¿¡ µû¸£¸é µ¶ÀÏÀÇ ÀÇ·á±â±â ½ÃÀå ±Ô¸ð´Â ¿¬°£ 358¾ï ´Þ·¯·Î À¯·´ Àüü ÀÇ·á±â±â ½ÃÀåÀÇ 25.6%¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ITA¿¡ µû¸£¸é µ¶ÀÏÀº ¹Ì±¹, ÀϺ»¿¡ ÀÌ¾î ¼¼°è 3À§ÀÇ ÀÇ·á±â¼ú ½ÃÀåÀ¸·Î À¯·´¿¡¼ °¡Àå Å« ±Ô¸ð¸¦ ÀÚ¶ûÇÕ´Ï´Ù.
À¯·´¿¡¼ °¡Àå ¸¹Àº Àα¸¸¦ º¸À¯ÇÑ µ¶ÀÏÀÇ ÀÇ·á ºÎ¹®Àº ¼ºÀå ±âȸ°¡ ¸Å¿ì Å« ¸Å·ÂÀûÀÎ ½ÃÀåÀÔ´Ï´Ù. Æò±Õ ¼ö¸íÀÌ ²ÙÁØÈ÷ Áõ°¡ÇÔ¿¡ µû¶ó ¾Ï, ¸¸¼ºÁúȯ ¹× ³ëÈ °ü·Ã Áúº´ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èÀºÇà ÀÚ·á¿¡ µû¸£¸é 2022³â¿¡´Â µ¶ÀÏÀÎÀÇ ¾à 22%°¡ 65¼¼ ÀÌ»ó °í·ÉÀÚ°¡ µÉ °ÍÀ̸ç, Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°è¾Ï¿¬±¸±â±Ý(WCRF) ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é µ¶ÀÏÀÇ ¾Ï ¹ßº´·ü(¿¬·É Ç¥ÁØÈ)Àº 10¸¸ ¸í´ç 281.9¸íÀ̸ç, 2020³â¿¡´Â 53¸¸ 8,140¸íÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ GLOBOCAN 2020¿¡ µû¸£¸é µ¶ÀÏÀº À¯¹æ¾Ï, Àü¸³¼±¾Ï, Æó¾Ï, ´ëÀå¾ÏÀÇ À¯º´·üÀÌ ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¸¸¼ºÁúȯ°ú ¾ÏÀÇ È®»êÀ¸·Î ÀÎÇÑ °Ç° ÀνÄÀÇ Çâ»óÀ¸·Î Áø´Ü ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ µ¶ÀÏÀº ÀÇ·á±â±â ¿¬±¸°³¹ßÀÌ È°¹ßÇÏ°í ¾Ï È¯ÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå ¼¼ºÐÈ
À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡º°·Î ¼¼ºÐȵ˴ϴÙ.
Á¦Ç°º°·Î´Â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº Àåºñ, ¼Ò¸ðǰ, ¾×¼¼¼¸®, ¼ÒÇÁÆ®¿þ¾î·Î ±¸ºÐµË´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®Àº 2022³â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¿ëµµº°·Î´Â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº ¾Ï Áø´Ü, À¯Àüº´ Áø´Ü, °¨¿°¼º Áúȯ Áø´Ü, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå¿¡¼ ¾Ï Áø´Ü ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº Áø´Ü ½ÇÇè½Ç, °è¾à ¿¬±¸ ±â°ü, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå¿¡¼ Áø´Ü ½ÇÇè½Ç ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.¿¡¼ Áø´Ü ½ÇÇè½Ç ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¹°¡º°·Î º¸¸é À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀº µ¶ÀÏÀÌ µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¶ÀÏÀÌ µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral ImagingÀº À¯·´ÀÇ Çü±¤ In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.
The Europe fluorescence in-situ hybridization (FISH) imaging systems market is expected to grow from US$ 268.0 million in 2022 to US$ 460.7 million by 2030. It is estimated to grow at a CAGR of 7.0% from 2022 to 2030.
Technological Advancements in Fluorescence in Situ Hybridization Imaging Fuel Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market
FISH imaging systems are witnessing a remarkable evolution due to the surge in technological advancements, which result in cutting-edge innovations transforming the landscape of genetic research and diagnostics. These advancements include enhanced optics, more sensitive and versatile fluorophores, and sophisticated automation features. Modern FISH imaging systems, integrated with these upgraded features, offer greater sensitivity, improved image resolution, and faster processing times. Moreover, these technological advancements have extended the application scope of FISH imaging from cancer diagnosis to genetic predisposition testing. In July 2021, BioView and Capio Biosciences collaborated to create a platform for collecting circulating tumor cells (CTCs) from whole blood. By integrating their technologies, these companies further worked on improving the CTC liquid biopsy downstream analysis. Similarly, BioView and Capio Biosciences, in collaboration, partnered with RUBYnanomed in December 2020 to create a unique imaging solution to accelerate the acceptance and adoption of CTC technology in clinics to enhance cancer detection. Thus, technological advancements in FISH imaging systems create significant opportunities for companies in the fluorescence in situ hybridization (FISH) imaging systems market.
Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Overview
The Europe fluorescence in-situ hybridization (FISH) imaging systems market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global market. The European Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is expected to grow significantly during the forecast period due to the strong medical device manufacturing capabilities and high cancer prevalence in different European countries. Germany is one of the most lucrative medical device markets across the world. According to International Trade Administration (ITA), the German medical device market accounts for ~US$ 35.8 billion annually or 25.6% of the total European medical device market. As per ITA, Germany is the third-largest medical technology market in the world after the US and Japan and is by far the largest European market.
Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive sector with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in cases of cancer and chronic and age-related illnesses. According to the data from The World Bank, in 2022, approximately 22% of Germans are aged 65 and above and prone to at least one chronic disease; this percentage is slightly higher than in any other European country. According to World Cancer Research Fund (WCRF) International, Germany had a significant incidence age-standardized rate of 281.9 cancer cases per 100,000, with 538,140 new cases in 2020. Additionally, as per GLOBOCAN 2020, Germany has a high prevalence rate of breast, prostate, lung, and colorectum cancer. Improved health awareness due to the prevalence of chronic diseases and cancer has increased the demand for diagnostics systems. Thus, the adoption of fluorescence in-situ hybridization (FISH) imaging systems is growing rapidly in Germany due to the flourishing medical device R&D landscape and rising cancer cases.
Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Revenue and Forecast to 2030 (US$ Million)
Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Segmentation
The Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into product, application, end users and country.
Based on product, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into instruments, consumables, accessories, and software. The consumables segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
In terms of application, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnostic, and others. The cancer diagnosis segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
Based on end user, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
By country, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented int o Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, and Applied Spectral Imaging are some of the leading companies operating in the Europe fluorescence in-situ hybridization (FISH) imaging systems market.